Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Ophthalmology

Life After Diagnosis: Long-Term Monitoring and Complications

At a Glance

Living with VKH disease requires ongoing monitoring to catch silent inflammation before it causes permanent vision loss. Regular eye scans and managing steroid side effects are essential for maintaining long-term remission and preventing complications like glaucoma and cataracts.

Living with Vogt-Koyanagi-Harada (VKH) disease is a long-term journey. While the initial “acute” phase is often the most frightening, the goal of long-term care is to maintain “remission”—a state where the immune system is quiet and your vision is protected [1].

Long-Term Eye Complications

Even with good initial treatment, chronic inflammation or long-term medication use can lead to secondary issues that require their own management:

  • Glaucoma: This is increased pressure inside the eye that can damage the optic nerve [2]. It is more common in patients with many recurrences or those who have been on steroids for a long time [3][4].
  • Cataracts: A clouding of the eye’s natural lens, which can cause blurred vision and glare [2][5]. Cataracts often develop due to both the disease itself and the steroids used to treat it [5].
  • Choroidal Neovascularization (CNV): In some cases, abnormal new blood vessels grow under the retina [2]. These vessels are fragile and can leak fluid or blood, causing sudden “wavy” or distorted vision [6].
  • Sunset Glow Fundus: This orange-red appearance of the back of the eye occurs when the pigment-producing cells have been permanently lost [7]. While it is an expected part of the convalescent phase for many patients, severe or progressive pigment loss is monitored closely because it correlates with a higher risk of long-term vision challenges [8][9].
  • Sugiura Sign (Perilimbal Vitiligo): This is a visible white halo of depigmentation on the sclera (the white of your eye) right around the edge of the cornea [7]. Like the sunset glow fundus, it is a marker of the disease’s “convalescent” (recovery/chronic) phase [10].

The Importance of Constant Vigilance

Because VKH can be “silent”—meaning the inflammation is active deep in the eye even when you feel fine—regular monitoring is essential [11].

  • Multimodal Imaging: Your doctor will use a combination of tests, such as EDI-OCT (to measure choroidal thickness) and ICGA (to look for dark spots of inflammation), to ensure the disease is truly quiet [12][13][14].
  • Catching Recurrences Early: Monitoring helps catch “subclinical” flares before they cause permanent damage. If a flare is caught early, your medications can be adjusted to stop it [11][15].

Lifestyle and Daily Management

Because your immune system is targeting pigment cells (melanocytes), protecting the remaining cells is a practical step you can take:

  • Sun Protection: Wear broad-spectrum, high-quality, UV-blocking sunglasses when outside to protect your eyes from further UV damage.
  • Skin Care: If you develop vitiligo (patches of white skin), those areas lack natural melanin and will burn easily. Apply high-SPF sunscreen to those areas regularly.

Your Long-Term Outlook

The prognosis for VKH has improved dramatically with modern medicine.

  • Visual Recovery: Patients who receive aggressive treatment early on have the highest chance of maintaining excellent vision [16][1].
  • Chronic vs. Acute: Those who experience frequent “flares” (chronic recurrent VKH) generally have a more difficult time and may require more intensive, long-term immunosuppression [5][17].
  • Beyond the Eyes: Even when the eyes are stable, some patients may still notice new patches of white skin (vitiligo) or hair. This doesn’t always mean the eye disease is active, but it is a sign the immune system is still reacting to pigment cells [7].

Successful long-term management is a partnership between you and your eye care team. By attending all follow-up scans, taking your medications as prescribed, and reporting any vision changes immediately, you can help ensure your VKH stays in check [18].

Common questions in this guide

Why do I need eye scans if my vision seems fine with VKH disease?
VKH can cause active, silent inflammation deep within the eye that you may not immediately notice. Regular imaging tests help your doctor catch and treat these hidden flares before they cause permanent damage.
What is a sunset glow fundus?
A sunset glow fundus is an orange-red appearance at the back of the eye caused by a permanent loss of pigment cells. It is a common sign that the disease has entered the chronic, convalescent phase.
Can VKH disease treatments cause other eye problems?
Yes, long-term use of steroids to control VKH inflammation can increase the risk of developing cataracts and secondary glaucoma. Your eye doctor will regularly monitor your eye pressure and lens clarity to manage these risks safely.
What does it mean if straight lines look wavy?
Distorted or wavy vision can be a sign of choroidal neovascularization, a condition where fragile new blood vessels grow under the retina and leak fluid. If you notice these vision changes, you should contact your eye care team immediately.
Do new patches of white skin mean my eye inflammation is back?
Not necessarily. Developing new areas of vitiligo or white hair shows your immune system is still reacting to pigment cells, but it does not always mean the active inflammation in your eyes has returned.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How often do I need to have my eye pressure checked to monitor for secondary glaucoma?
  2. 2.Does my most recent OCT or ICGA show any signs of 'silent' inflammation despite my vision feeling stable?
  3. 3.If I develop cataracts due to steroid use, when is the safest time to consider surgery relative to my disease activity?
  4. 4.What are the early signs of choroidal neovascularization (CNV) that I should look for at home (e.g., using an Amsler grid)?
  5. 5.Is my 'sunset glow fundus' stable, or is the pigment loss continuing?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Acute phase Vogt-Koyanagi-Harada syndrome resistant to corticosteroid therapy in an adult female patient.

    Kurt ZE, Argin MA

    Archivos de la Sociedad Espanola de Oftalmologia 2025; (100(11)):723-727 doi:10.1016/j.oftale.2025.08.003.

    PMID: 40780442
  2. 2

    Clinical characteristics and long-term outcomes of Vogt-Koyanagi-Harada disease in pediatric age group.

    Bezci Aygun F, Akgoz Koyuncuoglu M, Kadayıfcılar S, Ozen S

    BMC ophthalmology 2025; (25(1)):509 doi:10.1186/s12886-025-04334-y.

    PMID: 41013312
  3. 3

    The Incidence and Presentation Features of Glaucoma in Vogt-Koyanagi-Harada Syndrome: A Systematic Review and Meta-Analysis.

    Abdelaal A, Hassan AR, Katamesh BE, et al.

    Ophthalmology. Glaucoma 2024; (7(6)):587-601 doi:10.1016/j.ogla.2024.06.005.

    PMID: 38964611
  4. 4

    Incidence and Management of Glaucoma in Vogt Koyanagi Harada Disease.

    Pandey A, Balekudaru S, Venkatramani DV, et al.

    Journal of glaucoma 2016; (25(8)):674-80 doi:10.1097/IJG.0000000000000400.

    PMID: 26967258
  5. 5

    Long-Term Outcomes of Pediatric Vogt-Koyanagi-Harada Disease.

    AlQahtani DS, Almutairi AH, Ababtain IS, et al.

    Ocular immunology and inflammation 2025; (33(10)):2257-2264 doi:10.1080/09273948.2025.2491562.

    PMID: 40334076
  6. 6

    A Case of Pneumatic Displacement with Gas Tamponade Performed for Macular Subretinal Hemorrhage Complicating Vogt-Koyanagi-Harada Disease.

    Kobayashi T, Fukumoto M, Takai N, et al.

    Case reports in ophthalmology 2020; (11(1)):143-150 doi:10.1159/000506436.

    PMID: 32308616
  7. 7

    Vitiligo as a First Sign of Vogt-Koyanagi-Harada Disease.

    Vukojević M, Vukojevic N, Vuković A, et al.

    Acta dermatovenerologica Croatica : ADC 2023; (31(4)):229-231.

    PMID: 38651852
  8. 8

    Chronic Recurrent Vogt-Koyanagi-Harada Disease and Development of 'Sunset Glow Fundus' Predict Worse Retinal Sensitivity.

    Abu El-Asrar AM, Al Mudhaiyan T, Al Najashi AA, et al.

    Ocular immunology and inflammation 2017; (25(4)):475-485 doi:10.3109/09273948.2016.1139730.

    PMID: 27003480
  9. 9

    Evaluation of microvasculature alterations in convalescent Vogt-Koyanagi-Harada disease using optical coherence tomography angiography.

    Fan S, Lin D, Hu J, et al.

    Eye (London, England) 2021; (35(7)):1993-1998 doi:10.1038/s41433-020-01210-5.

    PMID: 33024324
  10. 10

    Iris Manifestations in Inadequately Treated Chronic Recurrent Vogt-Koyanagi-Harada Disease.

    Chee SP, Win MZA

    Ocular immunology and inflammation 2022; (30(5)):1116-1122 doi:10.1080/09273948.2020.1870701.

    PMID: 33561370
  11. 11

    Identification of Underlying Inflammation in Vogt-Koyanagi-Harada Disease with Sunset Glow Fundus by Multiple Analyses.

    Murata T, Sako N, Takayama K, et al.

    Journal of ophthalmology 2019; (2019()):3853794 doi:10.1155/2019/3853794.

    PMID: 31687197
  12. 12

    OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY REVEALS PARADOXICALLY DECREASING CHOROIDAL THICKNESS AND INCREASING BLOOD FLOW IN REMITTING VOGT-KOYANAGI-HARADA SYNDROME.

    Fayed AE, Gerges TK

    Retina (Philadelphia, Pa.) 2022; (42(9)):1788-1795 doi:10.1097/IAE.0000000000003525.

    PMID: 35552322
  13. 13

    Common practice patterns in the diagnosis and management of Vogt-Koyanagi-Harada syndrome: a survey study of uveitis specialists.

    Choo CH, Acharya NR, Shantha JG

    Frontiers in ophthalmology 2023; (3()):1217711 doi:10.3389/fopht.2023.1217711.

    PMID: 38983079
  14. 14

    Vogt-Koyanagi-Harada disease is always bilateral: reports of unilateral cases failed to use choroidal investigations showing subclinical involvement of the fellow eye.

    Papasavvas I, Herbort CP

    Journal of ophthalmic inflammation and infection 2021; (11(1)):6 doi:10.1186/s12348-021-00237-3.

    PMID: 33559795
  15. 15

    Delayed-onset unilateral Vogt-Koyanagi-Harada syndrome: a multimodal imaging appraisal.

    Verma S, Thakur H, Azad SV, Kumar V

    BMJ case reports 2021; (14(2)) doi:10.1136/bcr-2020-238623.

    PMID: 33568408
  16. 16

    EFFICACY OF COMBINED SYSTEMIC CORTICOSTEROID AND EARLY IMMUNOMODULATORY THERAPY WITHIN THREE MONTHS OF ONSET IN VOGT-KOYANAGI-HARADA DISEASE.

    Park HS, Park HY, Lee CS, et al.

    Retina (Philadelphia, Pa.) 2022; (42(12)):2361-2367 doi:10.1097/IAE.0000000000003617.

    PMID: 36394890
  17. 17

    Long-term Outcomes of Uveitis Associated with Vogt-Koyanagi-Harada Disease in the Pediatric Age Group.

    AlBloushi AF, AlEnezi SH, Al Owaifeer AM, et al.

    Ocular immunology and inflammation 2022; (30(7-8)):1669-1677 doi:10.1080/09273948.2021.1933074.

    PMID: 34184966
  18. 18

    Bilateral Iris Depigmentation and Ocular Hypotony as End-Stage Manifestations of Untreated Vogt-Koyanagi-Harada Disease.

    Cuevas M, de-la-Torre A, Córdoba A

    Ocular immunology and inflammation 2018; (26(7)):1101-1106 doi:10.1080/09273948.2017.1320411.

    PMID: 28548582

This page provides educational information on managing Vogt-Koyanagi-Harada disease long-term. Always consult your ophthalmologist or rheumatologist before making changes to your monitoring schedule or treatment plan.

Get notified when new evidence is published on Vogt-Koyanagi-Harada disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.